Prolight Diagnostics AB (NGM:PRLD) 1-Year Sharpe Ratio: -0.99 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:PRLD Prolight Diagnostics AB NGM:PRLD
31 GF Score
Price kr17.90
! 1 Warning Sign
View Full Analysis

What is Prolight Diagnostics AB 1-Year Sharpe Ratio?

Prolight Diagnostics AB NGM:PRLD +2.29% 31 1-Year Sharpe Ratio is -0.99 as of Aug. 02, 2026. GuruFocus rates NGM:PRLD with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-02), Prolight Diagnostics AB's 1-Year Sharpe Ratio is -0.99.

Prolight Diagnostics AB  (NGM:PRLD) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Prolight Diagnostics AB 1-Year Sharpe Ratio Related Terms

NGM:PRLD vs ISRG, BDX, MDLN: 1-Year Sharpe Ratio Comparison

For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prolight Diagnostics AB 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Prolight Diagnostics AB's 1-Year Sharpe Ratio falls into.


NGM:PRLD
31GF Score
Prolight Diagnostics AB NGM:PRLD
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prolight Diagnostics AB 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.99 mean?
Prolight Diagnostics AB (NGM:PRLD) has a 1-Year Sharpe Ratio of -0.99 as of Aug. 02, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Prolight Diagnostics AB and its competitors.
Is Prolight Diagnostics AB's 1-Year Sharpe Ratio too high?
Prolight Diagnostics AB's current 1-Year Sharpe Ratio is -0.99. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's 1-Year Sharpe Ratio compare to ISRG and BDX?
Prolight Diagnostics AB's 1-Year Sharpe Ratio of -0.99 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Prolight Diagnostics AB and its competitors. Prolight Diagnostics AB's current 1-Year Sharpe Ratio is -0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current 1-Year Sharpe Ratio of -0.99. The current 1-Year Sharpe Ratio is -0.99. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current 1-Year Sharpe Ratio is -0.99 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prolight Diagnostics AB Business Description

Address Gasverksgatan 3A, Lund, SWE, 222 29
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score

Get the complete analysis for NGM:PRLD

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.90
Price